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Background. Differentiation of embryonic stem cells (ESCs) into specific cell types with minimal risk of teratoma formation
could be efficiently directed by first reducing the differentiation potential of ESCs through the generation of clonal, self-
renewing lineage-restricted stem cell lines. Efforts to isolate these stem cells are, however, mired in an impasse where the lack
of purified lineage-restricted stem cells has hindered the identification of defining markers for these rare stem cells and, in
turn, their isolation. Methodology/Principal Findings. We describe here a method for the isolation of clonal lineage-
restricted cell lines with endothelial potential from ESCs through a combination of empirical and rational evidence-based
methods. Using an empirical protocol that we have previously developed to generate embryo-derived RoSH lines with
endothelial potential, we first generated E-RoSH lines from mouse ESC-derived embryoid bodies (EBs). Despite originating
from different mouse strains, RoSH and E- RoSH lines have similar gene expression profiles (r2 = 0.93) while that between E-
RoSH and ESCs was 0.83. In silico gene expression analysis predicted that like RoSH cells, E-RoSH cells have an increased
propensity to differentiate into vasculature. Unlike their parental ESCs, E-RoSH cells did not form teratomas and differentiate
efficiently into endothelial-like cells in vivo and in vitro. Gene expression and FACS analysis revealed that RoSH and E-RoSH
cells are CD9hi, SSEA-12 while ESCs are CD9lo, SSEA-1+. Isolation of CD9hi, SSEA-12 cells that constituted 1%–10% of EB-derived
cultures generated an E-RoSH-like culture with an identical E-RoSH-like gene expression profile (r2 = 0.95) and a propensity to
differentiate into endothelial-like cells. Conclusions. By combining empirical and rational evidence-based methods, we
identified definitive selectable surface antigens for the isolation and propagation of lineage-restricted stem cells with
endothelial-like potential from mouse ESCs.
Citation: Lian Q, Yeo KS, Que J, Tan EKW, Yu F, et al. (2006) Establishing Clonal Cell Lines with Endothelial-Like Potential from CD9hi, SSEA-12 Cells in
Embryonic Stem Cell-Derived Embryoid Bodies. PLoS ONE 1(1): e6. doi:10.1371/journal.pone.0000006
INTRODUCTION
The pluripotency of mouse embryonic stem cells (ESCs) to
differentiate into cells from all three germ layers makes ESCs an
ideal source of cells for regenerative therapy for many diseases and
tissue injuries [1,2]. However, this property of ESCs also poses
a unique challenge of having to generate therapeutically
efficacious quantity of appropriate cell types without being
contaminated by potentially deleterious cell types. In this regard,
lineage-restricted stem cells as therapeutic agents for regenerative
medicine offer several distinct advantages over pluripotent ESCs.
One, they are not pluripotent and therefore, cannot form
teratoma. Two, lineage-restricted stem cells unlike ESCs, can
only differentiate into a limited number of cell types, and
differentiation into the target cell types will therefore be more
efficient. Third, lineage-restricted stem cells being stem cells will be
able to self-renew and therefore could potentially be maintained as
a renewable source of cells in a similar manner as ESCs. In
addition, lineage-restricted stem cells unlike terminally differenti-
ated cell types can undergo in situ differentiation and will therefore
integrate better into the recipient target tissue.
ESCs can be induced to differentiate in vitro into lineage-
restricted stem cells types[3–8]. However, to date, only neural
stem cells can be clonally expanded in a homogenous culture[9] A
major hindrance to the derivation of lineage-restricted stem cells
from ESCs is the lack of highly purified tissue stem cells to identify
defining surface markers for rare tissue stem cells and this in turn
has greatly hinder their isolation. Nevertheless, there have been
some success in circumventing this limitation by inserting reporter
genes into lineage-specific gene loci [10–15], or selecting for
surface receptors known to be important in early tissue de-
velopment e.g. Flk-1 in hematopoiesis and vasculogenesis [16–18].
However, CD73+ human mesenchymal stem cell population is, to
date, the only lineage-restricted stem cell population to be
prospectively isolated from ESC by markers and propagated as
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a self-renewing population in culture[18]. To isolate clonal ESC-
derived lineage-restricted cell lines with endothelial potential and
the capacity for self-renewal in vitro, we had to use a combination
of empirical and rational evidence-based methods to gradually
circumvent the lack of definitive selectable markers. We have
previously isolated RoSH embryonic cell lines with endothelial
potential from early mouse embryos using an empirical approach
based on two premises[19]. The first is stochastic and predicts that
lineage-restricted stem cells with endothelial potential are likely to
be enriched in early embryos as the cardiovascular system is the
first functional system in the developing embryos. Second, the self-
renewing capability of putative lineage-restricted stem cells will
manifest as colonies of steadily dividing and uniformly looking
cells. The previously described RoSH cell lines with endothelial
potential were derived from 5.5 to 6.5 dpc mouse embryos[19].
Since ESC-derived embryoid bodies (EBs) are developmentally
analogous to early post-implantation embryos[20], we rationalized
that exposing EBs to the empirical protocol for deriving RoSH cell
lines could also generate RoSH-like cells. Several RoSH-like lines
termed E-RoSH lines were generated; these lines were highly
similar to RoSH lines. They do not express pluirpotency-
associated genes, failed to induce teratomas in immunodeficient
mice and differentiate readily into endothelial-like cells. Using
genome-wide gene expression profiling and FACS analysis, we
identified RoSH/E-RoSH cells as CD9hi, SSEA-12 while ESCs
were CD9lo, SSEA-1+. The selection criteria of CD9hi and SSEA-
12 were stringent enough to isolate putative E-RoSH cells from
differentiating ESC culture for the establishment of E-RoSHL cell
lines.
METHODS
Derivation of E-RoSH cell lines
E14 ESCs were induced to differentiate to form EBs using the
methycellulose-based approach[21]. Day 3 to day 6 EBs were
harvested, dissociated into single cell suspensions by collagenase
digestion [22] and plated on at a density of 1–56105cells per
10 cm feeder plate in RoSH media consisting of 400 ml DMEM
(Cat No: 10313-021) , 100 ml FCS (Cat No: 1049-024), 5 ml
Penicillin-streptomycin-glutamine (Cat No: 10378-016), 5 ml non-
essential amino acids (Cat No: 11140-050), 0.5 ml b-mercap-
toethanol (Cat No: 21985-023) (Gibco, Grand Island, New York).
After about a week, the cells proliferated and differentiated into
a complex mixture of cell types. Colonies of rapidly dividing cells
resembling embryo-derived RoSH cells were picked and expanded
sequentially to a 48-well plate, 24-well plate, 6-well plate and then
a 10 cm plate. The culture from each colony was named E-
RoSH1, 2, 3…in the sequence in which each culture was
established. Each of these cell cultures were then replated at 10–
100 cells per 10 cm plate. Colonies were then selected and
expanded to establish sublines that were named based on their
parental lines e.g. E-RoSH1.1, 1.2, 1.3, etc. For suspension
cultures, 16106 cells were plated on 10 cm bacterial Petri dishes
that were placed on an orbital shaker. Alkaline phosphatase assay
were performed using assay kits from Chemicon (Temecula,
California) and Bioassay Systems (Hayward, California). Chromo-
somes counting was performed as previously described[22]
RT-PCR analysis
Total RNA was prepared using standard protocols and were
quantified using RiboGreen RNA Quantification kit (Molecular
Probes, Eugene, Oregon). Quantitative RT-PCR was performed
using TaqManH primers (Applied Biosystems, Foster City, CA).
The Taqman primer ID for each gene analyzed was Pou5f1-
Mm00658129_gH; Sox2-Mm00488369_s1; Tdgf1-Mm00783944
_g1; Hesx1-Mm00439312_g1; Gata4-Mm00484689_m1; Kit-
Mm00445212_m1; Pdgfra-Mm00440701_m1; Tek-Mm00443242
_m1; Afp-Mm00431715_m1; Fabp2-Mm00433188_m1; Foxa2-
Mm00839704_mH; Sox17-Mm00488363_m1; Isl1-Mm00627860
_m1; Neurog3-Mm00437606_s1; Pax6-Mm00443072_m1; Pcsk1-
Mm00479023_m1.
Western Blotting
Total protein was isolated using standard protocols and 30 mg cell
lysates were separated by SDS-PAGE, transferred to nitrocellulose
membrane and incubated with goat anti-Oct3/4 (Santa Cruz
Biotechnology,sc-8628), goat anti-Sox2(sc-17320), rabbit anti-
Nanog ( Chemicon, AB5731), or mouse anti-b-actin antibodies
(Chemicon, MABP501) followed by incubation of the relevant
HRP-conjugated secondary antibodies and then a HRP enhanced
chemiluminescent substrate, ECS (Pierce, Rockford, IL) for
visualization.
Illumina gene chip analysis
Total RNA (2 mg) from each sample of E-RoSH2.1 p6 and p10, E-
RoSH3.2 p2 and p7, RoSH2 p9 and p13, E-RoSHL1 p5 and p6,
and E14 mESCs p15 and p16 cultures were converted to
biotinylated cRNA using the Illumina RNA Amplification Kit
(Ambion, Inc., Austin, TX) according to the manufacturer’s
instructions. Samples were purified using the RNeasy kit (Qiagen,
Valencia, CA). Hybridization to the Sentrix Mouse Refseq-8
Expression BeadChip (Illumina, Inc., San Diego, CA), washing
and scanning were performed according to the Illumina BeadSta-
tion 500x manual. The data were extracted, normalized and
analyzed using Illumina BeadStudio provided by the manufactur-
er. Transcript signals that were below the limit of detection (LOD)
at 99% confidence were eliminated as genes not expressed.
In vitro endothelial differentiation
Endothelial differentiation of E-RoSH cells and acetylated LDL
uptake by differentiated E-RoSH cells were performed as
previously described [19]. In vitro differentiated E-RoSH vascular
structures were fixed in formalin, and immunostained for vWF
using polyclonal, rabbit-generated antibody and Envision+
System-peroxidase (DakoCytomation, Gostrup, Denmark) and
counterstained with Mayer’s hematoxylin, or Tie-2 and CD34
using rabbit anti-Tie-2 and goat anti-CD34 (Pharmingen, San
Diego, California) respectively, followed by FITC-conjugated anti-
rabbit/goat antibody (Chemicon, Temecula, California), and
counterstained with PI.
In vivo endothelial differentiation
16106 ESCs were transplanted subcutaneously into SCID mice.
At three weeks when ESC-derived tumors were about 0.5–1 cm in
diameter, 16105 E-RoSH cells labeled with QdotH nanocrystals
(655 nm emission) using a QtrackerH Cell Labeling Kit (Quantum
Dot Corp, Hayward, CA) were injected into the ESC-derived
teratoma. Three days later, the mice were euthanized with an
overdose of anesthesia and the tumors were removed. The tumors
were fixed in 4% paraformaldehyde and cryosectioned at 20 mm
thickness. The sections were assayed for Tie-2 immunoreactivity
using using rabbit anti-Tie-2 (Santa Cruz Biotechnology, Cat
No:sc-9026) followed by FITC-conjugated rabbit anti-rat antibody
(Chemicon, Temecula, California), and counterstained with
DAPI. The sections were analyzed by confocal microscopy.
ESC-Derived Tissue Stem Cells
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Surface antigen analysis during differentiation
Cell surface antigens on E-RoSH cells before and 60 hours after
induction of differentiation on matrigel were analyzed using flow
cytometry. The cells were tryspinized for 5 minutes, centrifuged,
resuspended in culture media and incubated in a bacterial
culture dish for 2–3 hours in a 37uC, 5% CO2 incubator. The
cells were then trypsinized for 1 minute, centrifuged, washed
with PBS, fixed in 4% paraformaldehyde for 0.5 hour at room
temperature, washed and blocked in 2%FCS for 0.5 hour at
room temperature with agitation. 1.56105cells were then
incubated with each of the following conjugated monoclonal
antibodies: Tie-2, Flk-1, CD34, c-Kit, Thy-1, Sca-1 (PharMin-
gen, San Diego, CA) for 90 mins at room temperature. After
incubation, cells were washed and resuspended in PBS. Non-
specific fluorescence was determined by incubation of similar cell
aliquots with isotype-matched mouse monoclonal antibodies
(PharMingen, San Diego, CA). Data were analyzed by collecting
20,000 events on a Cyan LX with WinMDI software. (Dako
North America, Inc., Carpinteria, CA).
Sorting for putative E-RoSH cells
Sorting for CD9hi SSEA-12 was performed one week after 5 days
old EBs have been plated on gelatinized plates. The cultures were
trypsinized for 7 mins, neutralized, centrifuged, resuspended in the
culture media and then plated on bacterial culture dish. After
2 hours at 37uC in CO2 incubator, the cells were harvested,
washed with PBS and incubated with CD9-PE and SSEA-1-FITC
(PharMingen, San Diego, California) for 40 mins at room
temperature. The cells were then washed with PBS and sorted
on a FACS Aria using FACS Diva software (BD Biosciences
Pharmingen, San Diego, CA).
RESULTS
Derivation of RoSH-like lines from ESCs
To derive RoSH-like cells from ESCs, we rationalized that since
our derivation of RoSH cell lines was most optimal when using 5.5
to 6.5 dpc mouse embryos[19], 3–6 days old ESC-derived
embryoid bodies (EBs) that are developmentally analogous to
early post-implantation embryos for the derivation of RoSH-like
cells would also be optimal for the derivation of RoSH-like cells
from ESCs[20]. Briefly, 3–5 days old ESC-derived EBs were
dispersed into single cells by collagense digestion and passaged
several times on gelatinized culture dish. After one or two weeks,
colonies of RoSH-like cells were often discernible enough to be
picked and clonally expanded (fig 1a; Methods). We observed that
5 days old EB was most efficient in generating RoSH-like colonies
(fig 1b). Nine ESC-derived RoSH (E-RoSH) lines were in-
dependently derived, five from CSL3 ES cell line and four from
E14 ES cell line. Unlike its parental ESCs, E-RoSH cells did not
have detectable alkaline phosphatase activity (fig 1c). Single cell
plating of two lines E-RoSH2 and E-RoSH3 generated clonal sub
lines E-RoSH2.1 and E-RoSH3.2 respectively and these sublines
were used for further characterisation (fig 1a). Both E-RoSH2.1
and E-RoSH3.2 lines have a strong modal chromosome number
of 40 at passage 10 after subcloning. E-RoSH cells were
morphologically similar to RoSH cells (fig 2a). Despite being of
different mouse genetic background, gene expression profiles of E-
RoSH2.1 and E-RoSH3.2 cells of 129Sv mouse strain and RoSH2
cells of C57BL6/J mouse strains were highly correlated (r2 = 0.93)
(fig 2b). As a point of reference, technical replicates using the same
RNA samples performed at 2–3 months apart have a correlation
coefficient of 0.96–0.98. The gene expression profiles of E-
RoSH2.1 and E-RoSH3.2 cells and their parental E14 ESCs have
Figure 1. Derivation of E-RoSH cell lines. (a) ESCs were plated singly on methycellulose based media to form EBs. At day 3–6, EBs were harvested,
dissociated by collagenase and cultured as a monolayer on gelatinized feeder plate. RoSH-like colonies with adherent fibroblast-like cells and ring-like
structures were selected and propagated on gelatinized plates to generate E-RoSH 1, 2, 3… Each of the cultures were then plated at a low density of
10–100 cells per 10 cm plate and single RoSH like colonies were picked to established sublines, E-RoSH 2.1, 2.2, 2.3. .. etc; b) A putative RoSH-like
colony consisting of adherent short fibroblast-like cells with characteristic ring-like cells (inset) expanding over time; c) Alkaline phosphatase staining
of E-RoSH2.1 and its parental E14 ES cells.
doi:10.1371/journal.pone.0000006.g001
ESC-Derived Tissue Stem Cells
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a lower correlation coefficient, r2 = 0.83 (fig 2c). 1115 genes were
found to be expressed in ESCs at .2.5 fold higher than in E-
RoSH cells. Statistically significant higher frequencies of these
genes (p,0.05) were associated with biological processes that can
be broadly classified as neural differentiation, embryo develop-
ment and metabolism (fig 2d), suggesting that the differentiation
potential especially neural differentiation potential of E-RoSH
cells was reduced relative to ESCs. In contrast, among the 1263
genes that were expressed in E-RoSH cells at .2.5 fold higher
than in ESCs, a statistically significant higher frequency of genes
(p,0.05) was associated with biological processes involved in
proteolysis, protein metabolism, cellular protein metabolism,
cellular macromolecule metabolism, macromolecule metabolism,
memory and vasculature development (fig 2e). Together, these
global gene expression analyses suggest that unlike their parental
pluripotent ESCs, E-RoSH cells have a reduced neural differen-
tiation potential and may have lost their pluripotency. Their gene
expression profile also suggested that they are better poised to form
vasculature than their parental ESCs.
Real time RT-PCR analysis of representative genes confirmed
that expression of pluripotency associated genes as Pou5f1, Hesx1,
Sox-2 and Tdgf1 were at least 102–7 lower in E-RoSH2.1 and E-
RoSH3.2 than its parental E14 ESC (fig. 2f)[23,24]. In contrast,
expression of several genes that are important in mesodermal
differentiation e.g. Gata-4, Kit, Tek, Pdgfra (fig. 2g), and
endodermal differentiation e.g. Afp, Fabp2, Foxa2 and Sox17
Figure 2. Characterisation of E-RoSH cell lines. a) Cellular morphology of E-RoSH2.1 and RoSH2 cells in sub-confluent cultures; b,c) Pairwise
comparison of global gene expression between E14 ESCs and E-RoSH2.1/E-RoSH3.2, and RoSH2 and E-RoSH2.1/E-RoSH3.2. Global gene expression
analysis of E14 ESCs, E-RoSH, RoSH were performed by hybridizing total RNA from two biological samples each of E14 ESCs, E-RoSH2.1, E-RoSH3.2,
and RoSH2 with Illumina BeadArray containing about 24,000 unique features; d) Biological processes in which 1115 highly expressed genes in ESCs
have statistically significant higher frequencies (p,0.05). The biological processes were (left to right): neuron differentiation, neuron development,
nervous system development, neuron maturation, nerve ensheathment, cellular nerve ensheathment, ionic insulation of neurons by glial cells,
myelination, transmission of nerve impulse regulation of action potential, neurophysiological process, neuron morphogenesis during differentiation,
neurite morphogenesis, axonogenesis, cell development, development, system development, cell maturation, cell differentiation, cellular
morphogenesis, regulation of gene expression, epigenetic Imprinting, gametogenesis, morphogenesis, sexual reproduction, cell-cell signalling,
cell communication, metabolism, cell organization and biogenesis, regulation of biological process, macromolecule catabolism, carbohydrate
catabolism, cellular carbohydrate catabolism, monosaccharide catabolism, hexose catabolism, glucose catabolism, glycolysis, cellular macromolecule
catabolism, cellular catabolism, alcohol catabolism, carbohydrate metabolism, cellular carbohydrate metabolism, monosaccharide metabolism,
hexose metabolism, glucose metabolism, main pathways of carbohydrate metabolism alcohol metabolism, generation of precursor metabolites and
energy, energy derivation by oxidation of organic compounds; e) Biological processes in which 1263 highly expressed genes in ESCs have statistically
significant higher frequencies (p,0.05). The biological processes were (left to right): proteolysis, protein metabolism, cellular protein metabolism,
cellular macromolecule metabolism, macromolecule metabolism, memory and vasculature development; f,g, h, i) Relative gene expression analysis by
quantitative RT-PCR analysis. The expression level was normalized against that of ESCs and expressed as a logarithmic function; j) Western blot
analysis for pluripotency-associated gene products in cell extracts of ESCs, EBs and E-RoSH2.1 cells.
doi:10.1371/journal.pone.0000006.g002
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were elevated (fig. 2h). Consistent with the global gene expression
analysis, many genes known to be induced in early ectodermal
differentiation of ESCs such as Isl1, Neurog3, Pax6 and Pcsk1
were not upregulated (fig. 2i). The much reduced expression of
pluripotency-associated genes in E-RoSH cells e.g. Pou5f1, Sox-2
and Nanog was confirmed by the undetectable level of their
protein products in total cellular extract from E-RoSH cells (fig. 2j).
Differentiation of E-RoSH lines
To evaluate the in silico gene expression prediction that E-RoSH
cells are poised to differentiate into vasculature, E-RoSH cells
were plated directly onto matrigel. Unlike their parental ESCs
which can be propagated and maintained in an undifferentiated
state when plated on matrigel in ESC media [25], plating of E-
RoSH2.1 and 3.2 cells or RoSH2 cells on matrigel in RoSH cell
media was sufficient to induce endothelial differentiation and the
formation of vascular-like tubules that covered the entire tissue
culture dish[19]. These E-RoSH2.1-derived tubules were patent
and cells lining the lumen endocytosed acetylated LDL (fig 3b) and
were immunoreactive for vWF (fig. 3c), Tie-2 (fig. 3d), and CD34
(fig. 3e)[26] (data not shown for E-RoSH3.2). Within 60 hours
after plating on matrigel, the proportion of E-RoSH2.1 cells that
expressed Tie-2 and Flk-1, the key receptors in the regulation of
embryonic vascular development[27] was dramatically increased
from ,1% of undifferentiated E-RoSH2.1 cells to 61.5% and
Figure 3. Differentiation of E-RoSH cells. In vitro differentiation a) Morphology of E-RoSH2.1 cell culture two weeks after plating E-RoSH2.1 cells on
matrigel coated plate, b) The patent E-RoSH2.1 derived tubular structures were labeled with CFDA, a cytoplasmic green fluorescent dye (Molecular
Probe, Eugene, OR) and propidium iodide, and viewed by confocal microscopy (left panel). The tubular structures were incubated with acetylated red
fluoresecent diI-labelled LDL (Molecular Probe, Eugene, OR) for 24 hours and counterstained with SYTOX GreenTM, a green fluorescent nuclear dye
(Molecular Probe, Eugene, OR) before analysis by confocal microscopy (right panel). c–e) Immunoreactivity for vWF, Tie-2 and CD34 on sections of E-
RoSH2.1 derived tubular structures. vWF immunoreactivity was visualized using HRP-based detection system. Brown precipitates indicate positive
staining. The nuclei were stained with Mayer’s hematoxylin. CD34 and Tie-2 immunoreactivities were detected using secondary antibodies
conjugated with FITC. Nuclei were counterstained with PI. f) Flow cytometry analysis of E-RoSH2.1 cells for endothelial markers before (right panels)
and 60 hours after (left panels) induction of differentiation by plating cells on matrigel. Nonspecific fluorescence was determined by incubation of
similar cell aliquots with isotype-matched mouse monoclonal antibodies or with secondary antibody alone. g) Gene expression during in vitro
differentiation of E-RoSH2.1 cells on matrigel as measured by quantitative RT-PCR analysis. Relative gene expression is normalized against that at time
0 and expressed as a logarithmic function. h) In vivo differentiation. 16105 E-RoSH2.1 cells labeled with QdotH nanocrystals (655 nm emission) were
injected into a ESC-derived teratoma that was induced in SCID mice. Three days later, the mice were euthanized and the tumors were removed. The
tumors were fixed in 4% paraformaldehyde and cryosectioned at 20 mm thickness. The sections were assayed for Tie-2 immunoreactivity using rabbit
anti-Tie-2 followed by FITC-conjugated goat anti-rabbit antibody, and counterstained with DAPI. i. A typical section of a capillary plexus in the
teratoma as viewed by phase contrast microscopy (top left panel), stained with DAPI, a nuclear stain (top right panel), stained with using rabbit anti-
Tie-2 (bottom left panel), and cells labelled with Qdot (bottom right panel). ii. Merging of the three fluorescent stains. Yellow fluorescence indicates co-
localisation of Qdot and FITC-conjugated antibody.
doi:10.1371/journal.pone.0000006.g003
ESC-Derived Tissue Stem Cells
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40.25%, respectively (fig. 3f). The proportion of cells that
expressed other endothelial surface antigens such as c-kit, thy-1,
Sca-1 were also increased. There was minimal increase in CD34+
cells within the first 60 hours after induction of differentiation.
Expression of endothelial genes such as Flk-1, Kit, Pdgfra and Tek
was also increased with increased immunoreactivity against the
gene products (fig. 3g).
To confirm the loss of pluripotency in E-RoSH cells, 16106 E-
RoSH2.1 or 3.2 cells were subcutaneously transplanted into SCID
or immunodeficient Rag1 2/2 mice. Unlike similar trans-
plantation of the parental ESCs that invariably generated a 2 cm
teratoma within three weeks, E-RoSH cells did not induced any
tumor formation during a two to nine-months’ observation. To
induce endothelial differentiation of E-RoSH cells in vivo, the E-
RoSH 2.1 cells were first labelled with a long term, cell-permeable
fluorescent cell label, Q-tracker, and then transplanted into
a growing parental ESC-derived teratoma. The rationale was that
a teratoma where ESCs are actively differentiating into tissues of
all three germ layers is likely to provide a microenvironment
conducive for differentiation into tissues of the three germ layers
including vascular tissues. Three days after transplantation, E-
RoSH cells were found to be extensively incorporated into the
capillary plexuses of the teratomas and were immunoreactive for
Tie-2 (fig. 3h). E-RoSH cells were also dispersed throughout the
teratomas but we could not identify the tissue type that they were
associated with.
Identification of CD9 as a selectable marker for the
isolation of E-RoSH cell lines
To develop a more definitive and reproducible protocol for the
isolation of E-RoSH cell lines, we analyzed the gene expression
profiles of RoSH2, E-RoSH2.1, E-RoSH3.2 and E14 ESCs by
Illumina microbead array (Data S1) for surface antigens that were
differentially expressed in RoSH-like cells and ESCs, and that
already have commercially available antibodies. We therefore
generated a list of top 20 highly expressed genes encoding CD
antigens (Table 1). Despite the relatively high transcript levels of
PDGFRa, Tie2, c-kit, CD59, CD63, CD44 and CD24 in RoSH
and E-RoSH cells, they were not immunoreactive against
PDGFRa, Tie2, c-kit, CD59, CD63, CD44 and CD24 (data not
shown). Gene expression analysis also predicted that CD9,
a plasma membrane-bound tetraspanin in mouse ESCs[28], was
more highly expressed in RoSH and E-RoSH cells and this was
confirmed by confocal muicroscopy of CD9 immunostained E-
RoSH2.1 and E14 ESCs (fig. 4a). Flow cytometry determined that
CD9 immunoreactivity in E-RoSH2.1 or RoSH2 cells was 101–2
fold higher than that in E14 ESCs (fig. 4b) (data not shown for
RoSH2 cells). In addition, expression of SSEA-1, an ESC-specific
antigen[29,30] was absent on E-RoSH2.1 cells (fig. 4a, b). Based
on the expression pattern of CD9 and SSEA-1, flow cytometry
readily resolved a 1:10 mixture of E-RoSH2.1 cells and E14 ESCs
into two distinct populations, CD9hi, SSEA12 and CD9lo, SSEA1+
(fig. 4b). To test if putative RoSH cells in adherent monolayer
culture generated by plating 5 day EBs could be isolated using
CD9 and SSEA-1 as selectable markers, the heterogenous
differentiating EB culture was sorted for CD9hi, SSEA12 cells
that routinely constituted about 1–10% of these heterogenous
cultures (fig. 5a). One isolated CD9hi, SSEA12 cell population was
plated on a gelatnized plate. It generated a morphologically
homogenous RoSH-like cell culture (fig. 5b) termed E-RoSHL1.
E-RoSHL1 has a population doubling time of about 12–15 hours,
and a gene expression profile that was almost identical to that of E-
RoSH with r2 = 0.95 (fig. 5c). Like E-RoSH cells, plating of E-
RoSHL1 cells on matrigel dramatically increased expression of
endothelial markers such as Tie-2, Flk-1, c-kit, Sca1 and thy1
Table 1. List of top 20 highly expressed genes encoding CD antigens generated by comparing gene expression profiles of E-RoSH
and RoSH cells with E14 ESCs.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Symbol Synonyms Fold change
Dpp4 Cd26;Dpp-4;THAM 103.13
Pdgfra CD140a;Pdgfr-2 94.46
Enpp1 CD203c;E-NPP1;Ly-41;M6S1;NPP1;Npps;PC-1;Pca;Pca-1;Pdnp1;ttw;twy 82.04
F3 CD142;Cf-3;Cf3;TF 37.34
Tek Cd202b;Hyk;Tie2 20.59
Vcam1 CD106;Vcam-1 20.52
Cd44 AW121933;HERMES;Ly-24;Pgp-1 15.45
Daf1 CD55;Daf-GPI;GPI-DAF 11.85
Cd151 PETA-3;SFA-1 10.71
Abhd5 1300003D03Rik;2010002J10Rik;CDS;IECN5;NCIE2 8.97
Kit Bs;c-KIT;CD117;Fdc;Ssm;Tr-kit;W 8.47
Itgav 2610028E01Rik;CD51 6.58
Cd59a Cd59;protectin 6.17
Cd9 6.08
Itga5 Cd49e;Fnra 4.47
Plaur Cd87;u-PAR;uPAR 4.46
Itga3 CD49C 4.07
Cd63 ME491 3.71
Tnfrsf1a CD120a;FPF;p55;p55-R;TNF-R;TNF-R-I;TNF-R1;TNF-R55;TNFAR;Tnfr-2;Tnfr1;TNFR60;TNFRp55 3.05
Cd24a HSA;Ly-52 3.02
DOI: 10.1371/journal.pone.0000006.t001..
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within 60 hours (fig. 5d) and they formed a network of vascular
structures that covered the entire culture dish after one week
(fig. 5e).
DISCUSSION
In this report, we described a strategy for generating non-
pluripotent cell lines with endothelial differentiation potential by
using a combination of empirical and rational evidence-based
approaches. The initial empirical derivation of RoSH cell lines
from embryos [19] and then E-RoSH lines from ESCs provided
the initial wherewithal to develop rational evidence-based
approaches for the isolation of E-RoSH cell lines from ESCs.
Although these approaches were highly reproducible in our hands,
it relied heavily on descriptive parameters and was therefore not
easily transferable to other laboratories. Nevertheless, this
empirical protocol generated the critical purified cells for
a genome-wide panning for candidate genes encoding surface
markers that were differentially expressed in RoSH-like cells versus
ESCs, and culminated in the identification of CD9hi SSEA-12 cell
population as RoSH-like cell population in differentiating EBs.
The identification of CD9 as a surface marker that mark
putative RoSH-like cells in a differentiating ESC culture was
unexpected as it was not the highest expressing gene in RoSH or
E-RoSH relative to ESCs and is a widely expressed gene[31–33].
This is further confounded by the observation that several highly
expressed genes e.g. Pdgfra and Tie-2 did not produce detectable
levels of protein product. The combination of positive selection for
Figure 4. Identifying selectable surface antigens for the isolation of putative RoSH-like cells from differentiating ESCs. a) Confocal microscopy of E-
RoSH2.1 cells (top) and E14 ESCs (bottom). The cells were counterstained with DAPI, a nuclear stain after immunostaining for anti-SSE4-1 antibody
conjugated with FITC and anti-CD9 antibody conjugated with PE. b) FACS analysis of i) E-RoSH2.1 cells, ii) E14 ESCs, iii) murine embryonic fibroblast
(MEF) and iv) 10:1 mixture of E14 ESCs and E-RoSH2.1 cells. The cells were labelled with anti-CD9 antibody conjugated with PE and anti-SSE4-1
antibody conjugated with FITC, and analyzed on a FACS Aria using FACS Diva software (BD Biosciences Pharmingen, San Diego, CA).
doi:10.1371/journal.pone.0000006.g004
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high CD9 expression with negative selection against mouse ESC-
specific marker, SSEA-1 proved to be highly specific for RoSH-
like cells in 5 day old EB-derived cell population as evidenced by
the identical gene expression profile and endothelial potential of
a CD9hi, SSEA12 cell isolate. We observed that CD9hi, SSEA12
cells were most abundant in cultures derived from ,5 days old
EBs (data not shown) suggesting that these cells were present
transiently during spontaneous differentiation of ESCs,. While
differentially expressed CD9 was a good selectable marker for
RoSH-like cells in a 5 day old EB-derived cell population, its wide
tissue expression in many embryonic tissues[31–33] precludes its
use as a marker to track putative RoSH-like cells in the developing
embryos that have much higher cellular diversity.
CD9 is one of 32 members in the tetraspanin family.
Tetraspanins play important roles in numerous various signalling
events that affect proliferation, apoptosis, cell morphology, motility
and tumour progression[34,35]. CD9 is expressed in many tissues
including hematopioeitic cells e.g B cells[31,36], platelets and
endothelial cells[37]; early implantation embryos including de-
cidual cells and in the endometrium[38]. It is also expressed on
mouse ESCs [28,32,39] and we demonstrated here that they were
expressed at 101–2 fold lower than in RoSH-like cells. This suggests
Figure 5. Derivation of E-RoSHL1 cell line from CD9hi, SSEA1lo cell population in EB culture. a) One week after plating 5 day old EBs on gelatinized
culture plates, the cells were harvested, labelled with anti-CD9 antibody conjugated with PE and anti-SSE4-1 antibody conjugated with FITC, and
sorted. CD9hi, SSEA1lo cells in the P1 quadrant were selected as putative RoSH cells and plated on gelationized feeder plate; b) Morphology of semi-
confluent E-RoSHL1 and E-RoSH2.1. Bar represent 15 mm; c) Pairwise comparison of global gene expression between E-RoSHL1 and E-RoSH cells.
Global gene expression analysis were performed by hybridizing total RNA from two biological samples each of E-RoSHL1, E-RoSH2.1 and E-RoSH3.2
with Illumina BeadArray containing about 24,000 unique features; d) Flow cytometry analysis of E-RoSHL1 cells for endothelial markers before (righ
panels) and 60 hours after (left panels) induction of differentiation by plating cells on matrigel. Nonspecific fluorescence was determined by
incubation of similar cell aliquots with isotype-matched mouse monoclonal antibodies or with secondary antibody alone; e) Morphology of E-RoSHL1
culture one week after induction of differentiation by plating on matrigel. Bar represents 50 mm.
doi:10.1371/journal.pone.0000006.g005
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that the ubiquitously expressed CD9 may be expressed at different
levels in a tissue-specific manner. The isolation of a lineage-
restricted ESC-derived stem cell line with endothelial-like potential
further suggests that CD9 which is associated with many aspects of
endothelial functions e.g. leukocyte adhesion and transendothelial
migration[40,41] is expressed at high levels in endothelial
progenitors and differentiated progeny. The 89% identity of
human and mouse CD9 protein sequences (NCBI HomoloGene
database) also suggests that RoSH-like cell lines from human
ESCs could be isolated by positive selection for CD9 in
conjunction with negative selection for a human ESC-specific
surface e.g. SSEA-4.
The derivation of RoSH and E-RoSH cell lines from mouse
embryo cultures and ESC-derived EB cultures respectively suggest
that differentiation of mouse embryos and ESCs in vitro generate
RoSH cells as one of the transitional lineage restricted cell types.
However, it remains to be determined if RoSH-like cell types are
generated during the normal course of embryonic development.
Attempts to determine if RoSH cells can participate in embryonic
development by injecting RoSH or E-RoSH cells into blastocysts
had not generated any chimeric mice (data not shown). More
definitive and tissue-specific markers than CD9 will be essential in
assessing if RoSH-like cells exist or are formed during normal
embryonic development. In addition, the upregulated expression
of genes associated with early endodermal and mesodermal
differentiation (fig 2g,h) suggests that beside endothelial differen-
tiation, E-RoSH cells may have the potential to differentiate into
endodermal and other mesodermal cell types. However, to date we
have not been able to generate cell E-RoSH-derived cell types that
resembled mature endodermal or other mesoodermal cell types.
In summary, we demonstrate here a methodology to circumvent
an impasse in isolating lineage-restricted stem cell lines from ESCs
where the isolation of lineage-restricted stem cells is hindered by
the lack of defining selectable markers which in turn, cannot be
identified for a lack of highly purified lineage-restricted stem cells.
The impasse was gradually resolved by first using an empirical
approach that relies on the stochastic differentiation of mouse
embryos or ESCs to establish lineage-restricted cell lines with
endothelial-like potential. These self-renewing cell lines make
possible a systematic genome-wide panning for specific selectable
markers that distinguish these cells from the parental ESCs. This
approach may be applied to the challenging task of isolating and
propagating increasing lineage restricted stem cells that generate
therapeutically useful cell types such as insulin producing cells.
SUPPORTING INFORMATION
Data S1 Microarray analysis of gene expression in RoSH-like
cells vs ESCs. Total RNA (2 mg) from each sample of E-RoSH2.1
p6 and p10, E-RoSH3.2 p2 and p7, RoSH2 p9 and p13, E-
RoSHL1 p5 and p6, and E14 mESCs p15 and p16 cultures were
converted to biotinylated cRNA using the Illumina RNA
Amplification Kit (Ambion, Inc., Austin, TX) according to the
manufacturer’s instructions. Samples were purified using the
RNeasy kit (Qiagen, Valencia, CA). Hybridization to the Sentrix
Mouse Refseq-8 Expression BeadChip (Illumina, Inc., San Diego,
CA), washing and scanning were performed according to the
Illumina BeadStation 500x manual. The data were extracted,
normalized and analyzed using Illumina BeadStudio provided by
the manufacturer.
Found at: doi:10.1371/journal.pone.0000006.s001 (4.12 MB
XLS)
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